A retrospective multicenter study analysing pralatrexate treatment outcomes in patients with relapsed/refractory T-cell lymphoma
Latest Information Update: 12 May 2021
Price :
$35 *
At a glance
- Drugs Pralatrexate (Primary)
- Indications T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 12 May 2021 New trial record